David A Carlin

Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease

Timothy F. Feltes, Allison K. Cabalka, H. Cody Meissner et al. · The Journal of Pediatrics · 2003 · 827 citations

Medicine, Cardiology, Pediatrics +17

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial

Nicole Sherry, William Hagopian, Johnny Ludvigsson et al. · The Lancet · 2011 · 489 citations

Medicine, Internal Medicine, Pharmacotherapy +11

Reduction of Respiratory Syncytial Virus (RSV) in Tracheal Aspirates in Intubated Infants by Use of Humanized Monoclonal Antibody to RSV F Protein

Richard Malley, John P. DeVincenzo, Octavio Ramilo et al. · The Journal of Infectious Diseases · 1998 · 242 citations · Full text

Veterinary Medicine, Infectious Diseases, Pediatrics +17

Teplizumab Preserves C-Peptide in Recent-Onset Type 1 Diabetes

William Hagopian, Robert J. Ferry, Nicole Sherry et al. · Diabetes · 2013 · 241 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacotherapy +14

Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia

K. N. Siva Subramanian, LEONARD E. WEISMAN, TORUNN RHODES et al. · The Pediatric Infectious Disease Journal · 1998 · 226 citations

Pharmacy, Pediatrics, Pharmacokinetics +16